The Society for Medicines Research announce the 2016 SMR Award for Drug Discovery is awarded to the Bristol-Myers Squibb team responsible for OPDIVO® (nivolumab), a fully human anti-programmed death receptor-1 (PD-1) antibody approved to treat several cancers. The award will be received by Dr Francis Cuss, Executive Vice President & CSO R&D, Bristol-Myers Squibb, who will deliver the SMR Award Lecture entitled ‘The Discovery, Development and Delivery of Opdivo’.
The symposium will also feature an international line up of speakers from AstraZeneca, J&J Belgium, GSK, Pfizer and Merck KgGA presenting on the discovery and development of novel therapeutic agents which have recently progressed towards or into clinical trials. The programme includes a variety of mechanistic approaches for the novel therapeutics including small molecules, monoclonal antibodies and a drug re-purposing and will cover therapeutics areas including oncology, anti-infectives, inflammation and anaemia. ​
The symposium will also feature an international line up of speakers from AstraZeneca, J&J Belgium, GSK, Pfizer and Merck KgGA presenting on the discovery and development of novel therapeutic agents which have recently progressed towards or into clinical trials. The programme includes a variety of mechanistic approaches for the novel therapeutics including small molecules, monoclonal antibodies and a drug re-purposing and will cover therapeutics areas including oncology, anti-infectives, inflammation and anaemia. ​
